The 3 forces that drove a remarkable, record-setting week on Wall Street

Beyond the Rally: The New Era of Geopolitical Trading Markets have always been sensitive to war and peace, but we are entering a phase of “hyper-velocity” reactions. When diplomacy succeeds, the bounce-back isn’t just a steady climb—it’s a rocket ship. We recently saw the S&P 500 erase nearly a 10% correction in a matter of … Read more

It turns out you DO need NYC millionaires

Despite campaign rhetoric suggesting otherwise, New York City Mayor Zohran Mamdani’s financial plans appear to rely heavily on revenue generated by high earners on Wall Street. Wall Street Bonuses and City Revenue Wall Street bonuses reached a record $49.2 billion in 2025, a 9% increase, according to New York State Comptroller Thomas DiNapoli. This surge … Read more

Mamdani’s tax-&-spend plans leave NYC bond investors leery

New York City is facing increasing financial pressure as investors begin selling off city debt, leading to falling prices and rising interest rates. This shift comes despite Mayor Mamdani’s initial support from lenders in January, even with his plans to significantly alter the city’s economy. Early Support Turns to Concern For the first weeks of … Read more

Biggest risk to the economy now? Goldman says it’s a stock market correction

The Stock Market Correction Risk Looms Over 2026 Economic Growth Goldman Sachs is sounding the alarm: a stock market correction poses the biggest near-term risk to the U.S. Economy’s continued expansion in 2026. Despite forecasting a 2.5% GDP growth for the year, driven by fiscal stimulus, looser monetary policy, and easing trade tensions, the firm’s … Read more

Berkshire Hathaway trims Apple stake, buys NYTimes stock in Buffett’s last moves as CEO

Buffett’s Berkshire Shifts Portfolio: Apple Trimmed, New York Times Added – What It Signals Warren Buffett’s Berkshire Hathaway made notable adjustments to its investment portfolio in the fourth quarter of 2025, reducing its stake in Apple and initiating a position in The New York Times. These moves, occurring during Buffett’s final quarter as CEO, offer … Read more

Market updates: Westpac quarterly profit hits $1.9b, AUD below 71 US cents again, ASX and Wall Street down

Why the ASX 200 Is Feeling the Tech‑Sell‑Off Pressure The latest market snapshot shows the ASX 200 slipping 0.8% to 9,043.5 points while Wall Street’s S&P 500 and Nasdaq tumble 1.5% and 2.1% respectively. The pull‑back mirrors a “late‑session tech sell‑off” on Wall Street, where heavyweight names such as Cisco saw shares plunge 11.8% after missing … Read more

Trump’s critical minerals quest is linked to AI ambitions

The New Cold War: How the Race for Critical Minerals is Reshaping Geopolitics and Investment The world is witnessing a quiet, yet intensely competitive, scramble for resources. It’s not about oil this time, but about the minerals essential for the technologies defining the 21st century – artificial intelligence, electric vehicles, and advanced defense systems. This … Read more

Apple (NASDAQ:AAPL) Delivers Impressive Q4 CY2025

Apple’s Q4 Beat: Is the Tech Giant Still a Buy? Apple (NASDAQ:AAPL) just delivered a strong Q4 performance, exceeding Wall Street’s revenue expectations with a 15.7% year-over-year increase to $143.8 billion. Earnings per share also surpassed estimates, coming in at $2.84 – a 6.4% beat. But in a rapidly evolving tech landscape, particularly with the … Read more

Software stocks enter bear market on AI disruption fear with ServiceNow plunging 11%

The AI Reckoning: Why Software Stocks Are Facing a Turbulent Future The recent sell-off in software stocks isn’t just a market correction; it’s a fundamental reassessment of value in the age of artificial intelligence. Investors are waking up to the possibility that the decades-long reign of predictable software revenue growth may be coming to an … Read more

Quiet Rally Or Value Trap? What The Market Is Signaling Now

Ligand Pharmaceuticals: Beyond the Quiet Climb – Is a Biotech Compounder Emerging? Ligand Pharmaceuticals (LGND) has been quietly gaining traction, a subtle ascent that’s piqued the interest of biotech investors. Unlike the volatile swings of meme stocks or the fanfare of blockbuster drug launches, Ligand’s recent performance feels…different. It’s a story of steady accumulation, a … Read more